CNR1 and myeloid sarcoma: Cannabinoids inhibit the release of cytokines via activation of CB2R and inhibition of inducible NOS as well as nitrites production in response to ECs blocker UCM707, CBRs agonist WIN 55212, and anandamide in a CBR-dependent manner supporting the role of cannabinoid in MS.